Cambridge Healthtech Institute’s 16th Annual

Optimizing Cell Culture Technology

Enhancing Knowledge for Increasing Yield

August 24-25, 2020


Cells need optimal conditions and appropriate processing to yield positive results. This ‘must-attend’ conference has become the place to discuss breakthroughs and share successful strategies for culturing cells and increasing titer. Industry experts provide insights into optimizing conditions, as well as cell biology in the effort to improve yield, while also addressing the future of cell culture in an expanding market where demand continues to increase. Sessions focus on genome engineering, modeling and computational insights, as well as monitoring and analyzing processes for CHO and other expression systems.

Preliminary Agenda


FEATURED PRESENTATION: Cell and Vector Engineering for Biologics Production by CHO Cells: Evaluating Diverse Strategies

David C. James, PhD, Professor & Director, Advanced Biomanufacturing Center, Chemical & Biological Engineering, University of Sheffield

CHO-Based Cell Culture Platform Development for Research: Addressing the Workflow Needs from Early Discovery to Final Candidate Selection

Saurabh Sen, PhD, Principal Scientist, Antibody Expression, Biotherapeutics Molecule Discovery, Boehringer Ingelheim Pharmaceuticals, Inc.

Analysis of Chromatin Accessibility in CHO Cells Using ATAC-seq

Colin Clarke, PhD, SFI Principal Investigator, National Institute for Bioprocessing Research and Training (NIBRT)

Characterization of Glutathione-Related Proteome in CHO Cells and Its Relationship with Productivity and Cholesterol Synthesis

Valentine Chevallier, MSc, Associate Scientist, Cell Culture Process Development, UCB Pharmaceuticals


Metabolic Flux Analysis during Galactose and Lactate Co-consumption Reveals Enhanced Energy Metabolism in Continuous CHO Cell Cultures

Alan Dickson, PhD, Professor, Biotechnology; Director, Centre of Excellence in Biopharmaceuticals, Chemical Engineering & Analytical Sciences, The University of Manchester

Uncovering Regulations Governing Metabolic Shift to Lactate Consumption in CHO Fed-Batch Cultures

Shelby Breen, MSc, Senior Associate Scientist, Process Development, Pfizer Inc.

High-Throughput Cell Culture Metabolite Analysis Using LC/MS

Zhiyuan Sun, MSc, Scientist, Analytical Development, Janssen Research & Development, Johnson & Johnson


Challenges of Delivering on Accelerated CMC Timeline from Commercial Process Development through Process Characterization – A Case Study

Gaurav Chauhan, MS, Associate Principal Scientist, BioProcess Development, Merck Research Labs

Rapid Generation of Production Cell Lines with Superior Titers and 99% Monoclonality for Complex Antibody Molecules

Anupam Singhal, PhD, Technology Development, Berkeley Lights, Inc.

Improving Product Quality through Cell Culture Process Intensification

Yan Wang, PhD, Senior Scientist, Drug Substance Technology, Amgen, Inc.


Creating a Robust, Continuous Process through Modeling, Cell Culture Media Design, and Omics

Sarwat Khattak, PhD, Senior Engineer III, Cell Culture Process Development, Biogen

From Product Microheterogeneity to Homogeneity Using Integrated Modeling Methodology and New Cell Culture Component

Bassem Ben Yahia, PhD, Senior Scientist, Upstream Process Sciences, UCB Pharma S.A.

Comprehensive Clinical Program Monitoring and Control Enabled by Non-Product Specific Upstream Raman Models

Chelsea Worley, MSc, Engineer, Cell Culture Development, Biogen

For more details on the conference, please contact:
Mary Ruberry
Senior Conference Director
Cambridge Healthtech Institute

Phone: (+1) 781-972-5421


For partnering and sponsorship information, please contact:

Companies A-K
Sherry Johnson
Senior Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-1359

Companies L-Z
Carolyn Cooke
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-5412

Premier Sponsors: